{
  "docId": "019de070-1b1e-715b-9181-3c5ed2b300ba",
  "docSlug": "b1852bb8f228b7adee18c4b9e730fd78",
  "documentTitle": "Calliditas Therapeutics | IPO Presentation Deck | 38 slides",
  "authorId": "calliditas-therapeutics",
  "authorName": "Calliditas Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 28,
  "pageCount": 38,
  "prevPage": 27,
  "nextPage": 29,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "The slide highlights the lack of targeted anti-inflammatory therapies for PBC.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-1b1e-715b-9181-3c5ed2b300ba/28",
  "deckHref": "/decks/019de070-1b1e-715b-9181-3c5ed2b300ba",
  "deckJsonHref": "/decks/019de070-1b1e-715b-9181-3c5ed2b300ba.json",
  "deckAnchorHref": "/decks/019de070-1b1e-715b-9181-3c5ed2b300ba#slide-28",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.95,
        "x": 0.04,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "Source: 1) Lindor et al, Hepatology 2009; 2) Kim et al, Gastroenterology 2000; 3) EASL PBC Clinical Practice Guidelines, Journal of Hepatology 2017; 4) Company estimate based on prevalence reported by Kim et al 2000 and Nguyen et al 2010.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6125b7e4-0855-4d97-9601-bbb25073a155",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.4,
        "x": 0.55,
        "y": 0.22
      },
      "kind": "image",
      "text": "Estimated prevalence map of the U.S.",
      "attrs": null,
      "subkind": "map",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e624f88f-1827-47d2-b4aa-b61556c7bbb7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.04,
        "y": 0.18
      },
      "kind": "list",
      "text": "The disease: Primary Biliary Cholangitis (PBC) is a progressive and chronic autoimmune disease of the liver. Early symptoms include fatigue, itchy skin and dry eyes/mouth. Later stages - liver stiffness, musculoskeletal pain, edema, jaundice and underactive thyroid.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "450d403d-6d94-4995-824e-d13ea1c0753c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.04,
        "y": 0.52
      },
      "kind": "list",
      "text": "Standard of care: Ursodeoxycholic acid (UDCA) and obeticholic acid (Ocaliva) are the only FDA-approved medical treatments for PBC. No targeted anti-inflammatory therapy is approved in the U.S. or Europe. Previous trials indicates that corticosteroids may alleviate symptoms and improve biochemical and histologic findings.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ecf0de07-2630-4bd6-a39c-49097a369a07",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.08,
        "x": 0.65,
        "y": 0.35
      },
      "kind": "metric",
      "text": "140,000",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d6fc47b4-68b6-4784-8c3d-437656e25462",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.1,
        "x": 0.82,
        "y": 0.3
      },
      "kind": "paragraph",
      "text": "Annual U.S. incidence 0.3 - 5.8 per 100,000",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f5bd33b6-2da4-4739-a2b3-bf2467c85dc6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.35,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Primary Biliary Cholangitis",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3cbf3006-95b9-4117-891d-ce1e01ff0927",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem-Agitate-Solve (PAS)",
      "slug": "problem-agitate-solve-pas",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "194960b7-04da-44e5-a98a-6333ab5a07bb",
      "evidence": "Standard of care: Ursodeoxycholic acid (UDCA) and obeticholic acid (Ocaliva) are the only FDA-approved medical treatments for PBC",
      "confidence": 0.6
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}